Shares of Compass Therapeutics CMPX have skyrocketed 108.3% in a month after the company announced updates regarding its ...

Compass Therapeutics, Inc.’s CMPX share price has surged by 14.18%, which has investors questioning if this is right time to ...

with reference to the functional unblinding issue – is thought to have contributed to pressure on Compass' share price, which was down 16% at the time of writing. Functional unblinding refers to ...

And yet, analysts think there is still substantial room for further growth. With four out of six analysts rating Compass a Buy, the consensus price target for this company is $11.80, a full 266.5% ...